Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03546231
Recruiting Observational

Characteristics and Prognosis of Moderate or Severe Tricuspid Regurgitation

NCT03546231 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Started
2018-03-15
Last updated
2026-06-15

Condition(s) studied

Tricuspid Valve Disease

Study summary

The tricuspid valve : its evaluation is relatively difficult in echocardiography and the management of tricuspid valve diseases remains poorly codified.

Eligibility

Sex
ALL
Min age
18 Months
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>18 ans * inclusion criteria: moderate or severe tricuspid regurgitation * exclusion criteria: Refusal to participate/ prior surgery of the tricuspid valve

Primary outcome measure(s)

  • Overall survival — 5 Years
    It corresponds to the delay between the diagnostic and the date of death.

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens-Picardie Amiens France Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy Recruiting
MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD Recruiting
Is Cap Assisted Endoscopy Useful in Acute Upper Gastrointestinal Bleeding ? Recruiting
Salivary Replication of BK Virus in Post-kidney Transplant Starting soon
Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock? Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03546231 on ClinicalTrials.gov ↗ ← All trials in France